Figure S1. Correlation of PPARγ with PFS in HGSOC patients receiving Platin and/or Taxol treatments and the correlation of PPARγ with ABCB1 in EOC patients. (A) Correlation of PPARγ with PFS by Kaplan-Meier analysis in patients with serous OVCA (Stage: 3+4, grade: 3) receiving (a) no chemotherapy, (b) Platin or (c) Taxol or (d) both treatments. (B) Correlation between PPARγ and ABCB1 in EOC in GEPIA2 database (n=426). PPARγ, peroxisome proliferator-activated receptor γ; PFS, progression-free survival; OVCA, ovarian cancer; EOC, epithelial ovarian cancer; ABCB1, a gene that encodes P-glycoprotein (P-gp); GEPIA, Gene Expression Profiling Interactive Analysis.

Figure S2. The proliferation of OVCAR3 or OVCAR8 cells with different treatments for different time. Proliferation assay of (A) OVCAR3 and (B) OVCAR8 cells treated with HATES, GW9662, Trog and KO143 or combinations for 24, 48, and 72 h, respectively. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; NS, not significant.

Figure S3. The body weights changes of mice in the animal experiments. The body weights of (A) BALB/c nude mouse models and (B) C57BL/6 mouse models were monitored every other day. The body weights of mice in each group on day 0 were set as 1 for calculation of the ratio. sh, short hairpin; nc, negative control; DDP, cisplatin.